YS Biopharma Co Ltd banner

YS Biopharma Co Ltd
NASDAQ:LSB

Watchlist Manager
YS Biopharma Co Ltd Logo
YS Biopharma Co Ltd
NASDAQ:LSB
Watchlist
Price: 0.627 USD -24.46% Market Closed
Market Cap: $2.6m

Wall Street
Price Targets

LSB Price Targets Summary
YS Biopharma Co Ltd

There are no price targets for LSB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
YS Biopharma Co Ltd Competitors:
Price Targets
FAST
Fastenal Co
2% Upside
LVS
Las Vegas Sands Corp
38% Upside
NNOX
Nano-X Imaging Ltd
243% Upside
VERK
Verkkokauppa.com Oyj
48% Upside

Revenue
Forecast

-5% / Year
Past Growth
128% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
-5% / Year
Past Growth
128% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 2 years the compound annual growth rate for YS Biopharma Co Ltd's revenue is -5%. The projected CAGR for the next 1 year is 128%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LSB's stock price target?
Not Available

LSB doesn't have any price targets made by Wall Street professionals.

What is YS Biopharma Co Ltd's Revenue forecast?
Projected CAGR
128%

For the last 2 years the compound annual growth rate for YS Biopharma Co Ltd's revenue is -5%. The projected CAGR for the next 1 year is 128%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett